menu
    • menu

    Company profile for Viridian Therapeutics

    NEW Drugs in Dev: 4
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Viridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s patient-centric model of innovation leverages proven biology and technology to efficiently allocate research and development resources while addressing strategic gaps related to access, delivery, quality of life, and efficacy in therapeutic areas of focus. Viridian’s most advanc...
    Viridian Therapeutics is advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s patient-centric model of innovation leverages proven biology and technology to efficiently allocate research and development resources while addressing strategic gaps related to access, delivery, quality of life, and efficacy in therapeutic areas of focus. Viridian’s most advanced program, VRDN-001, is an anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody in development for thyroid eye disease (TED).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Viridian TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    221 Crescent Street Suite 401 Waltham, MA 02453
    Telephone
    Telephone
    617-272-4600
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.viridiantherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/viridiantx/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ViridianThera

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Viridian Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
    Viridian Announces Inducement Grants Under Nasdaq LR 5635(c)(4)

    08 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260108064915/en/Viridian-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    08 Jan 2026
    Share Share
    Viridian Therapeutics Prepares for Transformational 2026
    Viridian Therapeutics Prepares for Transformational 2026

    06 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260106202623/en/Viridian-Therapeutics-Prepares-for-Transformational-2026

    BUSINESSWIRE
    06 Jan 2026
    Share Share
    Viridian Therapeutics Gets Priority Review For Veligrotug BLA
    Viridian Therapeutics Gets Priority Review For Veligrotug BLA

    22 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251222159703/en/Viridian-Therapeutics-Announces-BLA-Acceptance-and-Priority-Review-for-Veligrotug-for-the-Treatment-of-Thyroid-Eye-Disease

    BUSINESSWIRE
    22 Dec 2025
    Share Share
    Viridian Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
    Viridian Announces Inducement Grants Under Nasdaq LR 5635(c)(4)

    05 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-05/viridian-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4

    PHARMIWEB
    05 Dec 2025
    Share Share
    Viridian Therapeutics Issues Inducement Grants Per Nasdaq LR
    Viridian Therapeutics Issues Inducement Grants Per Nasdaq LR

    07 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251107767864/en/Viridian-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

    BUSINESSWIRE
    07 Nov 2025
    Share Share
    Viridian Therapeutics Unveils Q3 2025 Financials & Recent
    Viridian Therapeutics Unveils Q3 2025 Financials & Recent

    05 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251105575655/en/Viridian-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Highlights-Recent-Progress

    BUSINESSWIRE
    05 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search